Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins
Radcliffe Medical Education are delighted to host a Multidisciplinary Team Roundtable. This roundtable chaired by Dr Yassir Javaid (East Midlands Clinical Network, UK) will review two case studies created by Prof Kausik Ray (Imperial College London, UK), which cover primary and secondary cardiovascular prevention in high-risk patients uncontrolled by statins.
Dr Javaid will be joined by Prof Lale Tokgözoğlu (Hacettepe University, Turkey), Prof Kausik Ray and Prof Ulrich Laufs (Leipzig University, Germany) on panel. The faculty will also host live audience polls for the cases, leading the faculty to review and discuss the results.
During the roundtable the faculty will discuss strategies to assess statin intolerance; CV outcomes associated with statin withdrawal; real-world data pertaining to guideline lipid targets; and emerging options for reducing CV events in high-risk patients.
The audience are encouraged ask questions throughout the live broadcast in the Q&A box provided and have their questions answered live by the faculty.
Achieving Lipid Targets & Managing CV Risk: Reassessing our way with Statins programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hours of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
*This educational programme is not intended for UK Healthcare Professionals
This broadcast is supported by an unrestricted educational grant by Daiichi-Sankyo
Welcome and introduction to participating faculty
Reviewing patient case studies, introducing live polling and result discussions.
Managing CV risk in statin intolerant or statin uncontrolled patients
Determining statin intolerance, reasons for statin withdrawal and CV outcomes associated with statin withdrawal.
Attaining lipid targets: How are we doing?
Reviewing guideline lipid targets, and real-world data.
Reducing major events in high-risk patients: Is statin intensification adequate?
Guideline recommendations and clinical data recap.
Revisiting patient cases
Discussion on polling results and audience Q&A
Wrap-up & Summary
Dr Yassir Javaid providing a summary and conclusion of this Roundtable.
Key Learning Objectives
- Knowledge: Recall prevalence of patients who are statin uncontrolled/intolerant
- Knowledge: Define the additive benefit of combination treatment compared with statin intensification
- Knowledge: Name the non-statin LLTs offering proven CV protection
- Competence: Identifying patients with indication for novel non-statin therapy
- Practice: Initiate lipid-lowering strategies proven to lower future CV events
- Lipid Management Specialists
- Primary Care
S. Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Professor Tokgözoglu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.
Professor Tokgözoglu has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE studies and has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee. She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She has won the “Prof. Dr. Seref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994.
Dr Yassir Javaid, Cardiovascular & Diabetes Lead Northamptonshire CCG, UK. Qualified from Cambridge University and completed his GP VTS training in Northampton. He has an interest in cardiology and echocardiography and was a clinical lead in the Northamptonshire Community Cardiology service, which had a focus on patients with heart failure and valve disease. Dr Javaid was named Pulse “GP of the Year” in 2015 for his work in reducing stroke emergency admissions in the East Midlands. He is also a council member of the British Heart Valve Society, accredited member of the British Society of Echocardiography and on the editorial board for the British Journal of Cardiology.
Ulrich Laufs is Chair and Professor of Cardiology at Leipzig University, Germany. Professor Laufs has published multiple experimental and clinical studies in the areas of ‘heart failure’, ‘heart and brain’ and ‘prevention’ with special interest in lipoprotein metabolism. He has received numerous honours, serves in several editorial boards of international cardiovascular journals and holds positions in cardiovascular societies.
Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials – Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease.
Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President-Elect of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.